



Imope

Express Mail Mailing Label No. EV289510060US

PATENT

Attorney Docket No. LEX-002C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies *et al.* CONF. NO.: 6802
SERIAL NO.: 10/005,212 GROUP NO.: 1646
FILING DATE: December 4, 2001 EXAMINER: Mertz, P.M.
TITLE: Heterodimeric Fusion Proteins Useful for Targeted Immune
Therapy and General Immune Stimulation

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Sir:

This paper is responsive to the Office action mailed from the U.S. Patent and Trademark Office on January 14, 2004, for the above-referenced patent application. Applicants enclose a Terminal Disclaimer and accompanying fee.

Amendments to the Claims are shown beginning on page 2 of this paper.

Remarks begin on page 4 of this paper.

04/29/2004 TSUBES 00000009 200531 10005212
01 00:00:00 86.00 DA

respectfully request that the rejection of the pending claims under 35 U.S.C. § 103(a) be reconsidered and withdrawn.

Conclusion


Claims 1-3 and 23-27 are pending and believed to be in condition for allowance.
Examiner Mertz is invited to telephone the undersigned attorney to discuss any remaining issues.

Respectfully submitted,

Date: April 14, 2004
Reg. No. 41,640

Tel. No.: (617) 248-7012
Fax No.: (617) 248-7100

3048903



Michael H. Brodowski
for Brian A. Fairchild
Attorney for Applicant(s)
Testa, Hurwitz, & Thibault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110